Theradiag Reports 2019 Revenue of €9.6 Million, Up 8.3%

Regulatory News:

THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, today reported its 2019 full-year consolidated revenue and its cash position as at December 31, 2019, figures which are currently being audited.

Consolidated 2019 revenue of €9.6 million

In thousands of euros		FY 2019		FY 2018		Change
Revenue*		9,647		8,911		+8.3%
of which Theranostics		4,431		4,010		+10.5%
of which Lisa Tracker kits in routine use		4,327		3,884		+11.4%
of which IVD		5,216		4,901		6.0%
*Figures currently being audited

Theradiag posted 2019 revenue of €9.6 million, up 8.3% from €8.9 million in 2018, in line with the company’s strategic priorities.

The Theranostics business posted strong growth of 10.5%, driven by sales of LISA TRACKER kits in routine use, which now account for the company’s recurring business in this segment. Sales of these kits reached a new milestone by generating total 2019 revenue of €4.3 million, up from €3.9 million in 2018. In the future, the Theranostics activity will be equivalent to this recurring business of kits sales, which is now firmly in place, therefore the company will no longer report on this KPI element separately.